Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V. Aredo, Heather A. Wakelee, Jessica A. Hellyer et al.|Journal of Thoracic Oncology|2021Cited by 131